ESRD (End Stage Renal Disease)NCT07217470
Fluid Status of ESRD Patients Undergoing Dialysis
An observational study of ESRD (End Stage Renal Disease), run by HemoCept Inc. at 1 site in United States.
Trial summary
The pilot clinical study will assess the correlation between fluid removal during dialysis and HemoCept device data. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- ESRD (End Stage Renal Disease)
- How many people
- 26 participants
- Where
- 1 siteUnited States
- Study dates
- 18 Aug 2025to 20 Nov 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Subjects between (and including) the ages of 18 and 75 and who meet all the Inclusion/Exclusion criteria
Who may be able to join
- Subject or representatives must have voluntarily signed the informed consent form before any study related procedures
- Subjects can be any gender, but must be between (and including) 18 and 75 years of age
- Subject has been on dialysis for more than 90 days and has been diagnosed with end stage kidney disease
- Subject is able and willing to provide informed consent and HIPAA authorization.
- Subject is able and willing to meet all study requirements
- Subject is able to place electrodes on bilateral deltoids and above the pant line on the waist.
Who cannot join
- Subject is pregnant, breast-feeding, or intends to become pregnant during the course of the study.
- Subject has a personal medical history that includes: Long Q-T syndrome, Cardiac channelopathies, genetic heart defects, Seizures, Acute untreated blood clotting disorders or acute untreated bleeding disorders
- Subject has had a heart transplant.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Pilot Clinical Study to Assess the Correlation Between Fluid Removal During Dialysis and HemoCept Device Data
The pilot clinical study will assess the correlation between fluid removal during dialysis and HemoCept device data.
- Conditions
- ESRD (End Stage Renal Disease)
- Medical subject headings
- Renal Insufficiency, Chronic
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation between dry weight changes and HemoCept device measurements.
The primary analysis will be conducted using HemoCept device readings taken before dialysis and at the end of dialysis, just prior to return of blood and fluid from the machine. The device data will then be assessed for its comparison to dry weight changes.
Measured: Before and after one dialysis session, over the course of 1 day
Secondary outcomes (1)
Device related adverse events, and the possible correlation of skin tone to device results.
-Device-related adverse events: device-related adverse events included all adverse eventsclassified as definitely, probably, possibly, or undetermined relation to the device or procedure
--Exploratory correlation of skin tone and device performance: Monk Skin Tone data will be collected to explore potential correlation between subject skin tone and HemoCept device readings.
Measured: Before and after 1 dialysis session, over the course of 1 day.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Oct 2025
- Study start18 Aug 2025
- Primary completion20 Nov 2025
- Study completion20 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ESRD (End Stage Renal Disease)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 26 participants (actual)
Sponsor and investigators
- Lead sponsor
- HemoCept Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Jusmin Patel, MD, Principal investigator, Sierra Nevada Specialty Care
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07217470
- Sponsor's protocol ID
- PRT-017
- Status last verified
- Dec 2025
- First submitted
- 16 Sep 2025
- Last updated
- 2 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: There is not a plan to make IPD available
Study at a glance
From the registry record, last updated by the sponsor on 2 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Pilot Clinical Study to Assess the Correlation Between Fluid Removal During Dialysis and HemoCept Device Data
- ClinicalTrials.gov ID
- NCT07217470
- Acronym / sponsor ID
- PRT-017
- Conditions
- ESRD (End Stage Renal Disease)
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 26 participants (actual)
- Lead sponsor
- HemoCept Inc.Industry (pharma, biotech, devices)
- Study start
- 18 Aug 2025 (actual)
- Primary completion
- 20 Nov 2025 (actual)
- Study completion
- 20 Nov 2025 (actual)
- First posted
- 16 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The pilot clinical study will assess the correlation between fluid removal during dialysis and HemoCept device data.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Subjects between (and including) the ages of 18 and 75 and who meet all the Inclusion/Exclusion criteria
Key inclusion criteria (6 listed)
- Subject or representatives must have voluntarily signed the informed consent form before any study related procedures
- Subjects can be any gender, but must be between (and including) 18 and 75 years of age
- Subject has been on dialysis for more than 90 days and has been diagnosed with end stage kidney disease
- Subject is able and willing to provide informed consent and HIPAA authorization.
- Subject is able and willing to meet all study requirements
Key exclusion criteria (3 listed)
- Subject is pregnant, breast-feeding, or intends to become pregnant during the course of the study.
- Subject has a personal medical history that includes: Long Q-T syndrome, Cardiac channelopathies, genetic heart defects, Seizures, Acute untreated blood clotting disorders or acute untreated bleeding disorders
- Subject has had a heart transplant.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Correlation between dry weight changes and HemoCept device measurements.
Time frame: Before and after one dialysis session, over the course of 1 day
The primary analysis will be conducted using HemoCept device readings taken before dialysis and at the end of dialysis, just prior to return of blood and fluid from the machine. The device data will then be assessed for its comparison to dry weight changes.
1 secondary outcome
Device related adverse events, and the possible correlation of skin tone to device results.
Time frame: Before and after 1 dialysis session, over the course of 1 day.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Dec 2025.
- Individual participant dataSharing planned: No. There is not a plan to make IPD available
Related trials for ESRD (End Stage Renal Disease)
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Recruiting
Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial
End Stage Kidney Disease (ESKD), Hypertension (HTN)
RecruitingObservational study
Physical Impairments in Children With Chronic Renal Failure
Chronic Kidney Failure, Chronic Kidney Diseases
RecruitingPhase 1
A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis
End Stage Renal Disease on Dialysis, Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jusmin Patel, MD principal investigator
Sierra Nevada Specialty Care
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of ESRD (End Stage Renal Disease), run by HemoCept Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation between dry weight changes and HemoCept device measurements. (time frame: Before and after one dialysis session, over the course of 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Dec 2025.